{
    "clinical_study": {
        "@rank": "107720", 
        "arm_group": [
            {
                "arm_group_label": "Nebulized amikacin", 
                "arm_group_type": "Experimental", 
                "description": "Participants receive nebulized amikacin BID for 14 days in combination with standard treatment."
            }, 
            {
                "arm_group_label": "Nebulized normal saline", 
                "arm_group_type": "Other", 
                "description": "Participants received nebulized normal saline BID for 14 days in combination with standard treatment."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a multi-centered, randomized, controlled study to assess the efficacy, indications\n      and adverse reactions of combined administration of nebulized amikacin in patients with\n      acute exacerbation of non-cystic fibrosis bronchiectasis and to evaluate whether inhaled\n      antibiotics are more likely to cause bacterial resistance."
        }, 
        "brief_title": "Combined Administration of Nebulized Amikacin in Patients With Acute Exacerbation of Non-Cystic Fibrosis Bronchiectasis", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-Cystic Fibrosis Bronchiectasis", 
        "condition_browse": {
            "mesh_term": [
                "Bronchiectasis", 
                "Fibrosis"
            ]
        }, 
        "detailed_description": {
            "textblock": "Objective: To assess the efficacy, indications and adverse reactions of combined\n      administration of nebulized amikacin in patients with acute exacerbation of non-cystic\n      fibrosis bronchiectasis and to evaluate whether inhaled antibiotics are more likely to cause\n      bacterial resistance.\n\n      Methods: Patients with acute exacerbation of non-cystic fibrosis bronchiectasis will be\n      randomly assigned to the observer group (participants receive nebulized amikacin BID for 14\n      days in combination with standard treatment) or the control group (participants receive\n      nebulized 0.9% saline BID for 14 days in combination with standard treatment). The primary\n      endpoint was bacterial clearance rate of sputum.\n\n      Expected results: Compared with the control group, bacterial clearance rate of sputum of the\n      observer Group will increase significantly."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female study subjects \u226518 years of age and \u226480 years of age;\n\n          -  Confirmed diagnosis of idiopathic bronchiectasis or postinfectious bronchiectasis;\n\n          -  Confirmation of infection with Pseudomonas aeruginosa at screening;\n\n          -  Are sensitive to amikacin;\n\n          -  Acute exacerbation of bronchiectasis.\n\n        Exclusion Criteria:\n\n          -  Bronchiectasis due to special causes;\n\n          -  Smokers;\n\n          -  Are associated with bronchial asthma;\n\n          -  Have any serious or active medical or psychiatric illness;\n\n          -  Be allergic to amikacin or not tolerant to nebulised amikacin(FEV1 reduces \u226515% after\n             inhaling amikacin."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02081963", 
            "org_study_id": "NCFB-AMK-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Nebulized amikacin", 
                "description": "Nebulized 0.2g of amikacin and 2 mL of normal saline twice a day for 14 days in combination with standard treatment.", 
                "intervention_name": "Amikacin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Nebulized normal saline", 
                "description": "Nebulized 3 mL of normal saline twice a day for 14 days in combination with standard treatment.", 
                "intervention_name": "Normal saline", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Amikacin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Nebulized amikacin;", 
            "Non-Cystic Fibrosis Bronchiectasis;", 
            "Bacterial clearance rate of sputum\uff1b", 
            "Acute exacerbation."
        ], 
        "lastchanged_date": "March 6, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Jinan", 
                    "country": "China", 
                    "state": "Shandong", 
                    "zip": "250012"
                }, 
                "name": "Qilu Hospital of Shandong University"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Controlled Study of Combined Administration of Nebulized Amikacin in Patients With Acute Exacerbation of Non-Cystic Fibrosis Bronchiectasis", 
        "overall_official": {
            "affiliation": "Director", 
            "last_name": "Yu Li, Professor", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Bacterial clearance rate of sputum", 
            "safety_issue": "No", 
            "time_frame": "up to day 14"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02081963"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Qilu Hospital", 
            "investigator_full_name": "Qian Qi", 
            "investigator_title": "assistant director", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Volume of sputum for 24 hours", 
                "safety_issue": "No", 
                "time_frame": "day 1, 7, 14"
            }, 
            {
                "measure": "The nature of sputum", 
                "safety_issue": "No", 
                "time_frame": "day 1, 7, 14"
            }, 
            {
                "measure": "The content of bacterial in sputum", 
                "safety_issue": "No", 
                "time_frame": "day 1, 7, 14"
            }, 
            {
                "measure": "Acute exacerbations", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "Change in forced expiratory volume in one second (FEV1) (Percent of Predicted for Age)", 
                "safety_issue": "No", 
                "time_frame": "day 1, 14"
            }, 
            {
                "measure": "Forced expiratory volume in one second (FEV1) (L)", 
                "safety_issue": "No", 
                "time_frame": "day 1, 14"
            }, 
            {
                "measure": "Forced vital capacity (FVC) (L)", 
                "safety_issue": "No", 
                "time_frame": "day 1, 14"
            }, 
            {
                "measure": "Adverse Events (AEs), Serious Adverse Events (SAEs), laboratory data", 
                "safety_issue": "No", 
                "time_frame": "day 7, 14"
            }
        ], 
        "source": "Qilu Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Qilu Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}